



CSL Research Acceleration Initiative

Seeking Expressions of Interest from Research Organizations

WHY COLLABORATE WITH CSL?



Global capabilities on your doorstep.



Work with one of the world's leading biotech companies.



Funding for successful proposals.



Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise.




Accelerate translation of your research to deliver new therapies to patients.

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL's **Research Acceleration Initiative** aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas.

Expressions of interest are sought from Business Development / Commercialization representatives across global research organizations that wish to participate in the 2025 CSL Research Acceleration Initiative.

The 2025 Research Acceleration Initiative will focus on innovative research projects that address unmet medical needs and are aligned with the following **Therapeutic Areas** and scientific **Platforms**:



CSL Research Acceleration Initiative

Additional Information

REGISTER YOUR RESEARCH ORGANIZATION

BD / Commercialization representatives from research organizations (universities, medical research institutes, hospitals) are invited to register their organization's interest to participate in the 2025 Research Acceleration Initiative by **emailing RAI@csl.com.au by 13th December 2024** expressing your interest to participate.

ASSIGN YOUR PRIMARY CONTACT

CSL requests that each research organization nominate **one** BD or Commercialization representative to be assigned as the primary contact for CSL.

CALLS FOR SCIENTIFIC PROPOSALS

CSL will work with nominated BD or Commercialization representatives from participating research organizations to seek scientific proposals that align with the focus areas for the 2025 Research Acceleration Initiative. Focus areas will be shared with registered organizations via webinars and flyers ahead of online applications opening. Scientists who wish to apply will be asked to submit a 300-word online abstract that outlines their proposal. Online submission of abstracts will open in January 2025.



LIMITATIONS ON ABSTRACT SUBMISSIONS

There is no limit on the number of abstracts that registered research organizations or individual researchers can submit.

FUNDING

Successful applicants will receive up to \$200,000 USD per year over two years (up to \$400,000 USD in total) to accelerate translation of their research. Funding is subject to successful negotiation and execution of a research collaboration and option agreement between CSL and the research organization.

Therapeutic Areas




Immunoglobulins




Transplant & Immunology



Hematology



Cardiovascular & Renal



Vaccines

Platforms

Plasma Protein Technology

Recombinant Protein Technology

Genetic Medicine

Vaccines Technology